2024 Fiscal Year Annual Research Report
Cardiac electrophysiology evaluation system for improved drug assessment
| Project/Area Number |
22K12801
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
李 俊君 大阪大学, 大学院工学研究科, 特任准教授(常勤) (10723786)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
劉 莉 大阪大学, 大学院医学系研究科, 特任准教授 (50380093)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Keywords | pluripotent stem cells / Cardiomyocytes / maturation / drug assessment |
|---|
| Outline of Annual Research Achievements |
This year, we utilized a 24-well traveling wave (TW) device to evaluate drugs with varying proarrhythmic risks. Traveling waves were successfully maintained in most wells. To validate the system, we tested both in-house iPSC line (253G1) and commercial iCell line. Compared to controls, the TW group, featuring enhanced maturation, showed a stronger response to isoproterenol, a drug known to increase heart rate, contractility, and cardiac output. The TW group also exhibited reduced sensitivity to verapamil and maintained low arrhythmia rates under ranolazine, both considered low-risk for torsades de pointes. Notably, increased arrhythmia was observed with quinidine and pimozide in the TW group, highlighting the system's improved accuracy and potential for cardiotoxicity screening.
|
